Device Trial Radar · NCT06620237
BIO|MASTER.CSP Study
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
152
Planned (sponsor's estimate)
Start
Oct 4, 2024
Primary completion
Oct 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Biotronik SE & Co. KGNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 1, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to test the clinical safety and performance of the Amvia pacemakers and the Solia CSP S lead when used for left bundle branch area pacing (LBBAP). The patient population consist of patients with cardiac pacemaker indication or cardiac resynchronization therapy indication and intended for implantation of a system with left bundle branch area stimulation. Participants will visit sites at enrollment in the study, at implantation and pre-hospital discharge, 1-, 6- and 12-month follow-up visits. Additional annual follow-up(s) may apply until study termination after regulatory approval of Solia CSP S. The total duration of the clinical investigation is expected to be until September 2027, with last patient out (LPO). During the visits the regular pacemaker and lead measurement are performed. A 12-lead ECG is recorded to document intrinsic and ventricularly paced heart rhythm to assess left bundle branch area pacing. Programming of the pacemakers will be done according to the participant´s therapeutical needs. The study will be conducted in approximately 18 sites in Europe, Australia and New Zealand where more than one physician per site are expected to participate.
Conditions
- Cardiac Pacing, Artificial
- Cardiac Pacemaker, Artificial
- Cardiac Resynchronization Therapy Devices
- Bradycardia
- Conduction Disorder
- Conduction Defect, Cardiac
- Heart Failure
Interventions
Implantation of the Solia CSP S pacing lead for LBBAPDevice
Left bundle branch area pacing using a Solia CSP S lead
Primary outcomes
What the sponsor says the trial is designed to measure.
- Amvia related SADE-d free rateTime frame: 6 months (183 days) after implantation
- Solia CSP S related SADE-d free rateTime frame: 6 months (183 days) after implantation
Locations
14 sites in 5 countries. Site status is shown where the registry gives one.
Integral Healthcare
Adelaide, Australia
Victorian Heart Hospital
Clayton, Australia
Lyell McEwin Hospital
Elizabeth Vale, Australia
11 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.